WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) today announced the appointment of Timothy D. Ocain, Ph.D. as Senior Vice President, New Product Strategy and Development. Dr. Ocain has over 25 years’ experience working in the pharmaceutical and biotechnology environment with experience in medicinal chemistry, pharmacology, biochemistry, program management and preclinical and early development across multiple therapeutic areas. He is co-author on over 30 publications and co-inventor on 17 patents.
“As Enanta begins to advance its internal candidates and seeks new development areas, Tim’s broad experience in drug discovery and business development will be an invaluable resource to the company,” stated Jay R. Luly, Ph.D. President and Chief Executive Officer.
Dr. Ocain has held senior management and executive positions across a wide range of small, mid and large cap biotechnology and pharmaceutical companies. Since 2010, Dr. Ocain has been an independent biotechnology consultant providing consulting services to a variety of companies. From 2006-2009, he was a member of the executive team as the Senior Vice President, Research and Development at Seaside Therapeutics, a company focused on neurodevelopmental disorders. Previously, he worked at Millennium Pharmaceuticals from 1998-2006 and held positions of increasing responsibility in drug discovery, program management and mostly recently held the position of Vice President, Inflammation Discovery. From 1993-1998 he worked at Procept, Inc, where he held senior level drug discovery positions, with additional responsibility for business development activities. Prior to Procept, he served in the medicinal chemistry department at Wyeth-Ayerst Research from 1986-1993.
Dr. Ocain received his B.S. in Biological Sciences from the University of Wisconsin-Eau Claire and his Ph.D. in Pharmaceutical Chemistry from the University of Wisconsin-Madison, and completed his post-Doctoral Fellowship in Chemistry at the University of Minnesota.
Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, Enanta has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a focus on developing an intravenous and oral treatment for hospital and community MRSA (methicillin-resistant Staphylococcus aureus) infections.